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We  have  prepared  a  number  of  human  monoclonal  autoantibodies  from 
patients with autoimmune disorders and from normal individuals (1,  2).  Many 
of these monoclonal autoantibodies were found to react with antigens in multiple 
organs.  One such multiple organ-reactive  (MOR) antibody, designated MOR- 
hl,  has  been  studied  extensively.  MOR-hl  is  an  IgM  mAb  that  reacts  with 
antigens in normal human anterior pituitary, thyroid, stomach, and pancreas (1). 
Studies on the nature of the antigens showed that MOR-hl  recognizes a  35 kD 
protein  in  the pituitary,  thyroid, stomach and pancreas and  growth  hormone 
(hGH)  in  the  pituitary (3).  Recently, we  prepared  a  mouse  monoclonai anti- 
idiotypic antibody designated 4E6 and showed that it reacted with the paratope 
of MOR-hl  (4).  Based  on  the  network  hypothesis (5),  if the 4E6  paratope  is 
complementary to the MOR-hl  paratope,  then the 4E6 paratope might have a 
conformation similar to epitopes on hGH and the 35 kD protein.  The current 
studies were initiated to see whether anti-idiotypic antibodies raised against 4E6 
would have autoantigen-binding specificities similar to that of MOR-hl. 
Materials and Methods 
Immunoreagents and Preparation of Anti-Anti-Idiotypic Ig.  Purified human growth hor- 
mone (hGH) was generously donated by Genentech, Inc., San Francisco, CA. The 35 kD 
protein from human stomach was purified as described earlier (3). All other reagents 
were commercially obtained (4). Preparation and affinity purification of human monoclo- 
nal autoantibody MOR-hl and murine monoclonai anti-idiotypic antibodies (4E6,  3E5, 
and 3F6) that react specifically with MOR-hI were described earlier (1, 4). 
Anti-anti-idiotypic Ig (anti-4E6) was prepared by immunizing (5 X) a rabbit with affinity- 
purified  4E6.  Serum  from  the  immunized rabbit  was  passed  through  a  protein  A- 
Sepharose 4B affinity column. The Ig bound to protein A was eluted and passed through 
a 4E6-affinity column. The eluate from this column was then passed sequentially through 
356-1-affinity column (to remove Ig class-specific antibodies), and 183-4- and MOPC-21- 
affinity columns (to remove anti-mouse (IgG~/K) subclass-specific antibodies). The entire 
purification procedure was done twice.  Ig from preimmune rabbit serum was affinity- 
purified on a protein A-Sepharose 4B column. 
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TABLE  I 
Specificity of the Reaction of Anti-4E6 with 4E6 
Countsbound* 
Wells coated with  lg class*  '~SI-labeled anti-rabbit Ig  e 
mouse mAbs 
Anti-4E6  Preimmune Ig  ! 
'251 Anti-mouse lg' 
4E6  IgG~ (k)  7,280 +  415  91 4. 61  5,657 3= 316 
3E5  lgG, (k)  274 3= 17  69 3= 73  5,726 4- 412 
3F6  IgG, (k)  300 4, 70  151  4. 10  6,169 4, 756 
183-4  lgG~ (k)  218 4- 32  174 3= 5  5,517 3= 243 
MOPC-21  IgG, (k)  187 4- 21  164 4- 12  5,558 +  151 
356-1  IgG~, (k)  276 4. 221  187 3= 34  5,754 +  229 
204-4  IgGh (k)  292 ±  226  161 4, 5  5,714 :!: 443 
* cpm 4, SD bound to wells. 
* Determined by Ouchterloney technique. 
| Anti-4E6 1 mg/ml, diluted 1:25, was added to wells that had been coated with the different mouse mAbs. The 
amount of rabbit lgG that hound was detected by incubation with "Sldabeled goat anti-rabbit IgG. 
! Preimmune rabbit lg. 
As a control, 'SSl-goat anti-mouse lgG was added to ensure that all wells were coated with approximately equal 
quantities of mouse lg. 
Solid-Phase RIA.  Microtiter plates were coated with antigen or antibody (1  ~g/well) 
essentially as described previously (4). Samples were tested in triplicate and the binding 
of m~I-labeled Ig was determined. 
Immunofluorescence.  The antibodies were tested for tissue reactivity by indirect im- 
munofluorescence (1, 3). 
Results 
The  specificity of affinity-purified anti-4E6  is  shown  in  Table  I.  Anti-4E6 
reacted with 4E6, but not with other mouse mAbs belonging to the same isotype 
and subclass. 
To see  whether anti-4E6  reacted with the  same epitope on  4E6  with which 
MOR-h 1 reacted, various concentrations of MOR-h 1 were mixed with a constant 
amount of anti-4E6 and added to 4E6-coated wells.  As seen in Fig.  1 A,  MOR- 
h 1, and not pooled human IgM, inhibited the binding of anti-4E6 to 4E6. The 
data suggest that anti-4E6 and MOR-h 1 interact with the same epitope on 4E6. 
To determine if the antigen-binding specificity of anti-4E6 was similar to that 
of MOR-hl,  the binding of these antibodies to wells coated with hGH,  35  kD 
protein, or gelatin  was tested. Table II shows that both anti-4E6 and  MOR-hl 
reacted with hGH and 35 kD protein, but not with gelatin. 
To test whether MOR-h 1 and anti-4E6 were reacting with the same or different 
epitopes on the hGH molecule, various concentrations of MOR-hl  were added, 
along with a  constant amount of anti-4E6,  to hGH-coated wells.  Fig.  1B shows 
that  MOR-hl  competed with  anti-4E6  for binding  to  hGH.  This argues  that 
MOR-hl  and  anti-4E6  are  recognizing the  same  epitope  or epitopes  in  close 
proximity to each other on hGH. 
To see whether the binding of anti-4E6 to hGH could be inhibited by 4E6, 
various concentrations of 4E6 were mixed with a  constant amount of anti-4E6 
and added to hGH-coated wells.  Fig.  1 C shows that the binding of anti-4E6 to 
hGH was inhibited by 4E6 and not by MOPC-21. Taken together, these exper- 
iments strongly suggest that both 4E6 and hGH are reacting with the paratope 
of anti-4E6. 1357 
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CONCENTRATION  OF  INHIBITOR  (~g/ml) 
F[CURE  1.  Competitive inhibition  experiments (A) Inhibition  of binding of anti-4E6 to 4E6 
by MOR-hl. Serial twofold dilutions of either MOR-hl (0) or pooled human IgM (&) were 
]nixed with an equal volume of anti-4E6 (10 /zg/ml) and added to 4E6-coated wells. Bound 
anti-4E6  was quantitated using lanI-labeled anti-rabbit lgG. Maximum binding was -3400 
cpm. (B) Inhibition of binding of anti-4E6 to hGH by MOR-hl. Serial twofold dilutions of 
either MOR-hl (0) or pooled human IgM (&) were mixed with an equal volume of anti-4E6 
(10 #g/ml) and added to hGH-coated  wells. Bound anti-4E6  was quantitated as described 
above. Maximum binding was ~4300 cpm. (C) Inhibition of binding of anti-4E6 to hGH by 
4E6. Serial twofold dilution of either 4E6 (0) or MOPC-21 (&) were mixed  with an equal 
volume ofanti-4E6 (10 #g/ml) and added to hGH-coated wells. Bound anti-4E6 was quantitated 
as described above. Maximum binding was ~3800 cpm. (D) Inhibition  of binding  of anti-4E6 
to 4E6 by hGH. Serial twofold dilution of either hGH (0) or gelatin (A) were mixed with an 
equal  volume of anti-4E6  (10 #g/ml) and added to 4E6-coated  wells. Bound anti-4Z6  was 
quantitated as described above. Maximum binding was -4800 cpm. 
To determine what proportion of the Ig molecules in our anti-4E6 preparation 
were capable of binding to hGH, different concentrations  of hGH were incubated 
with a constant amount of anti-4E6 and then added to 4E6-coated wells. Fig. 1 D 
shows  that  the  binding of anti-4E6 to  4E6  was  inhibited by hGH  but not by 
gelatin. Moreover, when anti-4E6 was absorbed with hGH, >90% of its reactivity 
with  the  tissues  was  eliminated  (not  shown).  Taken  together,  these  studies 1358  ESSANI  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Reactivity of Anti-4E6 with hGH and 35kD Protein 
First antibody  Second antibody* 
Wells coated with:* 
hGH  35 kD protein  Gelatin 
Anti-4E6  Anti-rabbit IgG  2,538 -+ 3710  3,812 -+ 350  96 + 9 
MOR-hl  Anti-human IgM  2,065 +  139  2,842 +  100  117 --. 42 
NR serum  I  Anti-rabbit IgG  168 +  25  154 +  21  179 +- 16 
Anti-hGH  Anti-rabbit IgG  6,417 + 931  84 _+ 3  77 -+ 11 
None  Anti-rabbit IgG  96 +  14  97 --. 4  106 -+ 11 
None  Anti-human IgM  99 "4" 8  98 :t: 8  92 --.  13 
* Wells were coated with 0.5/~g/well of either hGH,  35kD protein, or gelatin and then incubated with the first 
antibody. 
* The binding of anti-4E6, normal rabbit serum and anti-hGH antibody was quantitated with J2SI-labeled anti- 
rabbit lgG, and the binding of MOR-hl was quantitated with E~I-labeled anti-human IgM. 
! cpm + SD bound to wells. 
M  Preimmune normal rabbit serum. 
FIGURE  2.  Indirect Immunofluorescence. Reactivity of MOR-h I  (A, C, and E) and anti-4E6 
(B, D,  and F) with stomach (A and B),  thyroid (C and D), and anterior pituitary (E and F). 
Original magnification x  100. 
strongly argue that the binding specificity for both 4E6 and hGH reside in the 
same Ig molecules of the anti-4E6 preparation and that the majority of them are 
of the internal  image type. 
To see whether anti-4E6 also reacts with multiple organs, normal tissues were 
stained with MOR-hl  and anti-4E6.  As seen in Fig.  2, both MOR-hl  and anti- 
4E6  reacted  with stomach  (Fig.  2, A and B),  thyroid  (C and  D),  and  anterior ESSANI  ET  AL.  BRIEF  DEFINITIVE  REPORT  1359 
pituitary  (Fig.  2, E  and  F).  By double immunofluorescence  (3),  the  same cells 
were stained by both antibodies (not shown). Thus, anti-4E6 is an IgG multiple 
organ-reactive antibody with a specificity similar to that of MOR-hl. 
Discussion 
Previously, we reported the production of human  IgM monocional autoanti- 
bodies  (Abl)  in  vitro  that  reacted  with  multiple  organs  (1,  2).  The  present 
experiments  show  that  animals  immunized  with  a  monoclonai  anti-idiotypic 
antibody  (Ab2)  to an  Abl  can  make  IgG  antibodies  that  have  MOR activity. 
Thus,  MOR antibodies are not an artifact of in vitro procedures,  nor are they 
limited to the IgM class. Moreover, these experiments suggest that it is possible 
to raise autoantibodies without immunizing the host with autoantigens. 
Studies from several laboratories have shown that Ab2 made to paratopes of 
Abl  that  react with certain  ligands (e.g.,  insulin and  Bis Q) can bind to corre- 
sponding receptors for these ligands and,  in some cases, can trigger an experi- 
mental autoimmune disease (6, 7).  It is thought that the paratope of these Ab2s 
are complementary to the paratope of Abl. Several groups have also made anti- 
anti-idiotypic antibodies (Ab3). These latter antibodies have shown several dif- 
ferent types of reactivity (5,  8).  Some are directed against framework determi- 
nants on Ab2 and do not show Abl  like activity; others react with the paratope 
of Ab2 but are not internal  images and  fail  to show Abl-like antigen  binding 
activity;  and  still  others  react  with  the  paratope  of Ab2  and  show  Abl-like 
antigen-binding  activity.  Our  Ab3  belongs  to  this  latter  Category.  The  4E6 
paratope (Ab2) appears to have a conformational resemblance to an epitope on 
hGH and  the  35 kD protein  and thus can elicit an antibody (Ab3) that  reacts 
with these ligands. 
Since some Ab2s have conformational  similarities  to the  ligands  with  which 
Abl  react, they have been used with success to elicit antibodies against viruses, 
trypanosomes,  and  histocompatibility  antigens  (9).  The  present  work and  the 
recent report by Zanetti et al.  (10) show that anti-idiotypic antibodies can also 
induce autoantibodies. This raises the possibility that stimulation of autoreactive 
B iymphocytes present in the normal  B cell repertoire (11) by Ab2 may be one 
of the  mechanisms  for  triggering  autoimmunity.  In  fact,  some  anti-idiotypic 
antibodies are  known  to  have public  specificity (4,  8),  and  several  Ig  families 
bearing specific idiotypes have been implicated in certain autoimmune diseases 
(12).  Along  these  lines,  it  is  interesting  to  speculate  whether  stimulation  of a 
family of B lymphocytes by broadly reactive anti-idiotypic antibodies could result 
in the production of a spectrum of autoantibodies with different organ specific- 
ities as in  systemic lupus erythematosus or polyendocrine disease.  If this turns 
out to be the case, then it is conceivable that clonal proliferation of a single anti- 
idiotypic antibody could trigger an autoimmune cascade (2). 
Summary 
MOR-h 1 is a human multiple organ-reactive (MOR) monocional autoantibody 
(Abl) that reacts with human growth hormone (hGH) and a 35 kD protein found 
in the anterior pituitary, thyroid, stomach, and pancreas.  4E6 is a mouse mono- 1360  ESSAN1  ET  AL.  BRIEF  DEFINITIVE  REPORT 
clonal anti-idiotypic antibody (Ab2)  that reacts with  the paratope of MOR-h 
and is ligand inhibitable.  In the present study, we immunized a rabbit with 4E 
and  purified an  IgG  fraction (anti-4E6)  from the  sera.  Competitive inhibitio 
experiments showed that anti-4E6 (Ab3) binds to the same epitope on 4E6 an 
to  the  same  antigens  (i.e.,  hGH  and  35  kD  protein)  as  does  MOR-hl.  B 
immunofluorescence, anti-4E6, an IgG antibody, shows the same multiple orga 
reactivity with tissues as does MOR-hl, an IgM antibody. From these and othe 
studies, we conclude that the 4E6 paratope (Ab2) has a  conformational reseat 
blance to an epitope on hGH and the 35 kD protein. This raises the possibilit 
that antibodies made in response to certain anti-idiotypic antibodies may be on 
of the mechanisms for triggering an autoimmune response. 
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